Chlamydia Infections (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections – Drugs In Development, 2021, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Abera Bioscience AB

Abivax SA

BlueWillow Biologics Inc

Erganeo

Eurocine Vaccines AB

Evofem Biosciences Inc

Genetic Immunity Inc

Lead Discovery Center GmbH

Merck & Co Inc

Microbiotix Inc

QureTech Bio AB

Traccine Pharmaceuticals

Vault Pharma Inc

Vaxine Pty Ltd

Yaso Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chlamydia Infections - Overview

Chlamydia Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chlamydia Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chlamydia Infections - Companies Involved in Therapeutics Development

Abera Bioscience AB

Abivax SA

BlueWillow Biologics Inc

Erganeo

Eurocine Vaccines AB

Evofem Biosciences Inc

Genetic Immunity Inc

Lead Discovery Center GmbH

Merck & Co Inc

Microbiotix Inc

QureTech Bio AB

Traccine Pharmaceuticals

Vault Pharma Inc

Vaxine Pty Ltd

Yaso Therapeutics Inc

Chlamydia Infections - Drug Profiles

(citric acid + lactic acid + potassium bitartrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ab-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ChlamyDerm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia Infections - Dormant Projects

Chlamydia Infections - Product Development Milestones

Featured News & Press Releases

May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021

Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia

Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention

Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate

Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan

Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate

Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021

Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Dec 17, 2020: Evofem Biosciences provides update on pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea

Dec 11, 2020: Evofem Biosciences announces orange book listing of two U.S. patents for Phexxi

Dec 03, 2020: The U.S. Department of Veterans Affairs awards contract to Evofem Biosciences for Phexxi

Oct 20, 2020: Evofem Biosciences announces first patient enrolled in pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea

Sep 14, 2020: Evofem Biosciences to present data at the 2020 STD prevention virtual conference from phase 2b trial of EVO100 for prevention of chlamydia and gonorrhea in women

May 12, 2020: Eurocine Vaccines receives notification of grant to prepare for the manufacture of the chlamydia vaccine candidate

May 07, 2020: Eurocine Vaccines presents end results from preclinical study with chlamydia vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chlamydia Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Chlamydia Infections – Pipeline by Abera Bioscience AB, 2021

Chlamydia Infections – Pipeline by Abivax SA, 2021

Chlamydia Infections – Pipeline by BlueWillow Biologics Inc, 2021

Chlamydia Infections – Pipeline by Erganeo, 2021

Chlamydia Infections – Pipeline by Eurocine Vaccines AB, 2021

Chlamydia Infections – Pipeline by Evofem Biosciences Inc, 2021

Chlamydia Infections – Pipeline by Genetic Immunity Inc, 2021

Chlamydia Infections – Pipeline by Lead Discovery Center GmbH, 2021

Chlamydia Infections – Pipeline by Merck & Co Inc, 2021

Chlamydia Infections – Pipeline by Microbiotix Inc, 2021

Chlamydia Infections – Pipeline by QureTech Bio AB, 2021

Chlamydia Infections – Pipeline by Traccine Pharmaceuticals, 2021

Chlamydia Infections – Pipeline by Vault Pharma Inc, 2021

Chlamydia Infections – Pipeline by Vaxine Pty Ltd, 2021

Chlamydia Infections – Pipeline by Yaso Therapeutics Inc, 2021

Chlamydia Infections – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Chlamydia Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports